2005.HK
Strong BuyFull HouseAI neutralSSY Group Limited · Healthcare · Hong Kong · $1.0B
HKD 2.76 +1.8% · close 6 Oct · scored 7 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
SSY Group is a large Chinese maker of intravenous infusion solutions and medical packaging, a scale leader in a steady, necessity product. An active buyback and small insider purchases signal management confidence. China's volume-based procurement keeps pressure on prices, though, and forward estimates were cut 3.9% over the past month, which weakens the case for earnings growth.
ABOUT SSY GROUP LIMITED
Read
SSY Group Limited is a leading pharmaceutical manufacturer in China, primarily focused on the research, development, production, and sale of intravenous solutions and other essential medicines. The company benefits from a large production capacity, extensive sales network, and adherence to stringent quality standards, providing a significant competitive advantage in the high-volume healthcare market. Its focus on indispensable medical products ensures stable demand and market relevance.
FINANCIAL SUMMARY (HKD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 6.4B | 6.5B | 5.8B | 4.2B | -13.5% | 4.4B | 4.7B | 5.2B | 11.5% |
| EPS (HKD) | 0.26 | 0.38 | 0.44 | 0.36 | 0.16 | -11.1% | 0.17 | 0.21 | 0.25 | 24.8% |
| Shares | — | 3.0B | 3.0B | 3.0B | 2.9B | -2.3% | 2.9B | — | — | — |
| Debt | — | 3.2B | 3.4B | 3.6B | 4.0B | 7.7% | 4.0B | — | — | — |
| Equity | — | 6.2B | 6.9B | 7.2B | 7.3B | 5.5% | — | — | — | — |
| Op CF | — | 733.7M | 925.7M | 491.0M | 635.0M | -4.7% | 984.1M | — | — | — |
| Inv CF | — | -402.7M | -640.2M | -521.8M | 77.0M | — | — | — | — | — |
| Fin CF | — | -190.5M | -304.6M | -295.4M | -293.7M | — | — | — | — | — |
Calmer than 73% of stocks we rank over the past year (29% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 2005.HK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 2005.HK | SSY Group Limited(you) | $1.0B | 90 | Strong Buy |
| 3613.HK | Beijing Tong Ren Tang Chinese Medicine Company Limited | $582M | 94 | Strong Buy |
| 0867.HK | China Medical System Holdings Limited | $3.3B | 87 | Strong Buy |
| 3320.HK | China Resources Pharmaceutical Group Limited | $3.4B | 95 | Strong Buy |
| 2633.HK | Jacobson Pharma Corporation Limited | $242M | 93 | Strong Buy |
| 3839.HK | CPBIO Holding Company Limited | $249M | 95 | Strong Buy |
| 0570.HK | China Traditional Chinese Medicine Holdings Co. Limited | $806M | 61 | Hold |
| 0460.HK | Sihuan Pharmaceutical Holdings Group Ltd. | $854M | 59 | Hold |
| 3933.HK | The United Laboratories International Holdings Limited | $1.9B | 67 | Buy |
| 2161.HK | JBM (Healthcare) Limited | $172M | 90 | Strong Buy |
Peer medians: ROE 5.7% · P/E 10.0x · Gross margin 43.2%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.